Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could two common vitamins tame the chaos of sepsis?

NCT ID NCT07786350

Disease control Sponsor: Universitas Sumatera Utara Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This trial tests whether giving thiamine (vitamin B1), vitamin C, or both, alongside standard care, can reduce harmful inflammation and tissue damage in adults with sepsis. The study will measure blood markers of inflammation and tissue remodeling before and after 72 hours of treatment, and track organ function and survival. If these vitamins help, they could offer a simple and affordable way to improve outcomes for critically ill patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
thiamine, ascorbic acid (vitamin C), and their combination
What this could lead to
If effective, this could point toward a simple, low-cost add-on treatment to reduce organ damage and improve survival in sepsis patients.
What could go wrong
This is a small, early-stage trial with only 40 participants, so results may not be conclusive or generalizable. The treatment is given alongside standard care, and its benefit is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Apr 2020

Finished

May 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older * Admitted to the intensive care unit with sepsis (Sepsis-3) * SOFA score \>= 2 * Arterial lactate \>= 2 mmol/L Exclusion Criteria: \* Known allergic reaction to thiamine or ascorbic acid

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sepsis and septic shock are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Sepsis toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sepsis and septic shock

Contacts and locations

Locations

  • Haji Adam Malik General Hospital

    Medan, North Sumatra, 20222, Indonesia

  • Universitas Sumatera Utara

    Medan, North Sumatra, 20222, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.